PULMONARY SURFACTANT MARKET ANALYSIS

Pulmonary Surfactant Market, by Type (Synthetic Pulmonary Surfactant,Animal Derived Surfactant), by Drug Type (Poractant alfa, Lucinactant, Calfactant), by Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)), by Route of Administration (Intratracheal, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5324
Pages :161
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Key Players

Key players operating in the global pulmonary surfactant market include Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech

Companies covered:

Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech